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Secondary Prevention in Patients with Peripheral Arterial
Disease: Are We Letting Our Patients Down?Patients with symptomatic peripheral arterial disease
(PAD) are at increased risk of cardiovascularmorbidity
andmortality.1 The Reduction of Atherothrombosis for
Continued Health (REACH) registry is an interna-
tional database of 70 000 outpatients with established
cardiovascular diseases, of which 8 000 have PAD.2
Nearly 16% of patients in the database had symptom-
atic disease involving >1 vascular bed.2 The incidence
of asymptomatic coronary artery disease is likely to be
even higher,3 thus atherosclerosis should be regarded
and managed as a systemic disease. Recent guidelines
recommend aggressive risk factor modification and
cardioprotective therapy (antiplatelet agents, statins,
angiotensin-converting enzyme inhibitors (ACEi) and
b-blockers) in patients with PAD.4 However, we are
not fully utilising opportunities to optimise risk factor
management in these patients.
In the REACH registry risk factor profile was con-
sistent across all diseased vascular beds and geo-
graphic regions studied, as was the underutilisation
of established lifestyle changes and therapies regard-
less of medical speciality. When medication use was
split by speciality, antiplatelets agents were used in
86.4% of patients recruited by vascular surgeons, sta-
tins in 62.3%, b-blockers in 34.2% and ACEi in 36.1%.
Except the use of antiplatelet agents, the prescription
of cardioprotective medication was low when com-
pared to other specialties.
Anaudit performed inourunit of 99patientswhoun-
derwentmajor non-cardiac vascular surgery (peripheral
bypass, carotid endarterectomy and abdominal aortic
aneurysm repair) suggests that opportunities for
secondary prevention at discharge are also missed. In
our cohort prescription rates for antiplatelet agents
(87.9%), statins (85.9%), b-blockers (29.3%) and ACEi
(42.4%) were similar to those in the REACH registry.
Screening for diabetes mellitus and hypercholesterol-
emia occurred in 78.8% and 61.8% of patients respec-
tively. Non-fasting glucose was elevated in 42.5% of
non-diabetic patients and despite treatment 31% had
a random total cholesterol >5.0 mmol/L (>200 mg/
dL). These trends are again similar to those found in
the REACH registry.1078–5884/000190+ 02 $32.00/0  2006 Published by Elsevier Ltd.This data indicates that there is a substantial gap
between established recommendations and actual
practice and opportunities for implementing second-
ary prevention for PAD patients are missed. In partic-
ular there is a reluctance of vascular surgeons to
prescribe cardioprotective drugs. This may be due to
inexperience with certain classes of drugs, especially
ACEi, and historical reasons. One such fallacy is the
use of b-blockers in PAD: evidence suggests they do
not cause a deterioration in claudication symptoms.5
While the value of perioperative b-blockade in im-
proving outcomes following non-cardiac vascular
surgery remains uncertain,6 many patients undergo-
ing vascular surgery will have a primary indication
for b-blockade, e.g. previous myocardial infarction.
Another concern is the incidence of renovascular
disease in PAD patients. The ‘Heart Outcomes Pre-
vention Evaluation’ (HOPE) investigators found that
ramipril significantly reduced the number of cardio-
vascular events in both symptomatic and asymptom-
atic PAD patients.7 Once these classes of drugs are
prescribed careful monitoring of blood pressure and
renal function are required over the following six
weeks.8 However the balance of risk and benefit
supports the use of these inhibitors in most patients.
These issues highlight the question as to whether
vascular surgeons are best placed to instigate such
measures for secondary prevention. The role of
antiplatelet drugs and statins in secondary prevention
is unequivocal and should be started in either the
in- or out-patient setting. Further reluctance to institute
therapy with certain classes of cardioprotective drugs
may reflect concerns in blood pressure that may occur
in the perioperative period.
Many of these difficulties would be addressed by
establishing multidisciplinary risk factor clinics that
could provide aggressive secondary prevention for
patients with PAD. They provide lifestyle advice
and pharmacological agents to treat the core set of
risk factors for cardiovascular disease.9 It is attractive
to suggest that these clinics could be run by a nurse
specialist who has easy access to vascular disease spe-
cialists (cardiologists, neurologists and diabetologists).
191Secondary Prevention and Vascular SurgeryFurther advice, including prescription of b-blockers,
might also be available from anaesthetists in pre-
admission clinics.
Secondary prevention can be implemented by the
family-care physician. In the UK recent national
guidelines issued by the Joint British Societies propose
definitive care pathways for patients with cardiovas-
cular disease.4 In addition the General Medical Ser-
vices Contract for family doctors in the UK is in part
linked to cardiovascular prevention quality indicators.
In summary, secondary risk factor prevention for pa-
tientswith PAD is suboptimal at the present time. Clear
responsibility for this with an emphasis on a systematic
approach encompassing all risk factors is required.Vas-
cular surgeons have numerous opportunities to imple-
ment this either themselves, or in a properly organised
risk factor clinic. A holistic approach to the manage-
ment of vascular disease is crucial for patient care.
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